Search published articles


Showing 1 results for Kabir

F Niknezhad, Mj Kabir, A Keshtkar, B Hazrati, N Kurdjazi, I Rezayyan, Ah Ankizeh,
Volume 1, Issue 2 (Autumn – Winter 2008[PERSIAN] 2007)
Abstract

Abstract Background and objectives: Vibrio Cholera is one of the causative agents that can easily lead to death if the appropriate therapeutic measures are not taken in time. The purpose of this study is to identify the antibiotic sensitivity of the isolated V. choleras from the patients during the outbreak of Cholera in Golestan province, 2005. Materials and Methods: The Subjects were 97 positive cultured samples sent by different laboratories of Golestan province health centers .First, these samples were confirmed with microbiological and biochemical tests. Then, their antibiotic sensitivity was examined by Kirby –Bauer method (12 routine drugs were used).To obtain better results, the tests carried out in parallel by two expert technologists. Results: The participants, aged 29.8 +- 16 years, are male (52.6%) and female (47.1%). The highest antibiotic susceptibility pattern is related to Cephotaxime (91.6%), Ceftizoxime (87.8%), Oxcy Tetracycline (76.1%) while the most antibiotic resistance is referred to Nalidixic Acid (84.5%), Fourazolidin (50.7%) and Erythromycin (50.7%). During outbreak, Antibiotic resistance was not increased. Both technologists reports regarding Ampicillin, Tetracycline, Nalidixic Acid (kappa of 94%, 89%, 82%, p value<0.05) have the most agreement while it is not true about Erythromycin and Fourazolidin disks. (Kappa 67% and 62%, p value<0.05) Conclusion: Because of the resistance of Vibrio cholera to different antibiotic agent, it is important to determine their pattern to control and prevent the spread of drug resistance species. Key words: Vibrio cholera, Inaba, antibiotic resistance, Golestan



Page 1 from 1     

© 2007 All Rights Reserved | Medical Laboratory Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.